2seventy bio, Inc. (NASDAQ: TSVT) reported Q4 EPS of ($0.37), $0.17 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $2.93 million versus the consensus estimate of $13.32 million.

For earnings history and earnings-related data on 2seventy bio, Inc. (TSVT) click here.